Auteurs : Burri C1, Ferrari G2, Ntuku HM1, Kitoto AT1, Duparc S1, Hugo P1, Mitembo DK1, Lengeler C1.
The American Society of Tropical Medicine and Hygiene
Am J Trop Med Hyg. 2014 Jul 28. pii: 14-0149. [Epub ahead of print]
Abstract Cases of delayed hemolytic anemia have been described after treatment with injectable artesunate, the current World Health Organization-recommended first-line drug for the treatment of severe malaria. A total of 350 patients (215 [61.4%] < 5 years of age and 135 [38.6%] ≥ 5 years of age) were followed-up after treatment with injectable artesunate for severe malaria in hospitals and health centers of the Democratic Republic of the Congo. A complete series of hemoglobin (Hb) measurements were available for 201 patients. A decrease in Hb levels between 2 and 5 g/dL was detected in 23 (11.4%) patients during the follow-up period. For five patients, Hb levels decreased below 5 g/dL during at least one follow-up visit. All cases of delayed anemia were clinically manageable and resolved within one month.